JMS CO.,LTD PRESS RELEASE
This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy
between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility forthis translation or for direct, indirect or any other forms of damages arising from the translation.

[Reference Translation]

July 14, 2023
Company name: JMS Co., Ltd.
Name of representative: Ryuji Katsura, President and Representative Director (Securities
code: 7702; Prime Market of Tokyo)
Inquiries:.
Jo Sueda, Executive Officer, Head of Corporate Affairs Division(Telephone: +81-82-243-5844)

Notice of Changing Subsidiary's Indirectly Owned SubsidiaryJMS Co., Ltd. hereby announces that JMS Singapore Pte. Ltd., our consolidated subsidiary, has decided to enter
into an equity transfer agreement today with Asahi Kasei Medical Co., Ltd. The agreement entails the acquisitionof the entire equity interest in Asahi Kasei Transfusion Technology Co., Ltd. ("AKTT"), a subsidiary of Asahi Kasei
Medical Co., Ltd. Please find the details below.
1. Reason for Acquisition of Equity Interest
We are currently engaged in the global manufacturing and distribution of products essential for blood managementbusiness, including blood bags used for blood preservation after blood donation and products required for bloodcollection and transfusion, which form a significant part of our core blood business. In many countries, including
Japan, blood bags with integrated leukocyte reduction filters are utilized to prevent adverse reactions duringtransfusions using blood derived from blood donations. The demand for such blood bags is expected to continue
growing. AKTT, leveraging the technology and know-how of Asahi Kasei Medical Co., Ltd.'s leukocyte reduction
filter "SepacellTM," primarily manufactures and sells leukocyte reduction filters for the domestic market in China.
To strengthen our business foundation and respond to expanding demand in a flexible and efficient manner, wehave decided to acquire all of AKTT's equity interest and make it our subsidiary. This strategic move allows us tointernalize the production of leukocyte reduction filters, which were previously sourced externally, and createsynergies through the integrated operation with blood bags. Furthermore, by assuming a new role in the supply ofleukocyte reduction filters, we aim to enhance our presence in the global blood management markets, thereby
expanding our business revenue.
2. Outline of Subsidiary to acquire the Equity Interest(1) Name.
JMS SINGAPORE PTE. LTD.
(2) Location.
440 Ang Mo Kio Industrial Park 1, Singapore, 569620(3) Job title and name ofTohru Sakoda, Managing Director
representative(4) Business description
Manufacture, Sales, Export and import of Medical Devices andPharmaceuticals.
(5) Capitalization.
SGD 16million (JPY 1,673million, converted 1SGD = JPY 104.58 As ofJune15,2023)
3. Outline of Transferred Sub-subsidiary(1) Name.
Asahi Kasei Transfusion Technology Co.,Ltd.
(2) Location.
No8 Xiangshanhe Road, Jingang Town, Zhangjiagang City,Jiangsu Province, 215632 China(3) Job title and name ofMasafumi Asakawa, General Manager
representative(4) Business description
Development, manufacture and sale of leukocyte reduction filters for bloodtransfusion.
- 1 -JMS CO.,LTD PRESS RELEASE(5) Capitalization.
CNY 111.63million (JPY 2,184million)(6) Date established.
October 13, 1999.
(7) Major shareholder andAsahi Kasei Medical Co., Ltd. 100%.
shareholding ratio(8) Relationship between Capital relationship
There is no capital relationship to be described.
the listed company and the Personnel relationship
There is no personnel relationship to be described.
company in question
Business relationship
There is no business relationship to be described.
(9) Consolidated operating results and consolidated financial condition of the company during the last threeyears
Fiscal year
Ended December
Ended December
Ended December
2020
2021
2022
Net assets
CNY 80,520,537
CNY 73,875,352
CNY 80,950,027(JPY 1,576 million)(JPY 1,446 million)(JPY 1,584 million)
Total assets
CNY 85,237,570
CNY 104,667,925
CNY 122,672,295(JPY 1,668 million)(JPY 2,048 million)(JPY 2,401 million)
Net sales
CNY 18,807,830
CNY 26,202,846
CNY 30,448,767(JPY 368 million)(JPY 513 million)(JPY 596 million)*The exchange rate is JPY 19.57 per CNY, as of June 15, 2023.
*Financial information after operating profit onward is not disclosed at the request of the counterparty.
4. Outline of the Counterparty to the acquisition of Equity Interest(1) Name.
Asahi Kasei Medical Co., Ltd.
(2) Location.
Hibiya Mitsui Tower, 1-2, Yurakucho 1-chome, Chiyoda-ku, Tokyo(3) Job title and name ofKen Shinomiya , Representative Director and President
representative(4) Business description
Development, manufacture and sale of medical equipment(5) Capitalization.
JPY 3,000 million(6) Date established.

July 24, 1974

(7) Net assets

JPY 76.3 billion (as of 31 March, 2022)(8) Total assets

JPY 99.8 billion (as of 31 March, 2022)(9) Major shareholder andshareholding ratio(10) Relationship between
the listed company and thecompany in question

Asahi Kasei Corp. 100%.
Capital relationship
Personnel relationship
Business relationshipApplicability to relatedparties

There is no capital relationship to be described.
There is no personnel relationship to be described.
There are business transactions between theCompany and its subsidiaries.
There is no applicable item to be described.

5. Number and Amount of Equity Interest to be Acquired and Status of Equity Interest Ownership Before and afterAcquisition(1) Ratio of equity interest0%before transfer(2) Ratio of equity interest
100%.
to be transferred(3) Acquisition amountThis information is not disclosed at the request of the counterparty. The
acquisition price has been determined following discussions between theparties, based on a value calculation by an external expert and after reasonableconsideration of the results of legal and financial investigations by externallawyers and certified public accountants.
(4) Ratio of equity interest
100.0%.
after transfer- 2 -JMS CO.,LTD PRESS RELEASE

6. Schedule(1) Contract signing date(2) Share transfer dateJuly 14, 2023
October 31, 2023 (plan)

7. Future Prospects
The impact of this transaction on consolidated performance for the financial year ending March 31, 2024 is minor.

For further information, please contact.
Corporate Strategy Office, Corporate Planning Group(Telephone) +81-82-243-9059(e-mail) pub-bpd@jms.cc- 3 -